CAST PHARMA Announces a New Office in Denmark

CAST PHARMACAST PHARMA, a premier European 3D pharmaceutical and biomedical animation production company, has announced the opening of the new office in Ballerup, Denmark. This new office will allow Cast Pharma to meet the growing demand in the Northern Europe pharmaceutical market and to improve services to existing clients.

"With the increase in technology capabilities and the rapidly growing demand on patient education as well as the health care professionals' continuous training needs, more and more pharmaceutical companies are moving to 3D visualization techniques to get their message across to their target audience and differentiate themselves from their competitors," commented CAST PHARMA owner, Mr. Stefan Wolf. "Our new office is represented by Mrs. Antje Madsen, a skilled, top line professional that will better serve our European clients and will allow us to meet the increasing demands of 3D mode of action animation production."

With the extended capabilities of its new office, CAST PHARMA will focus on promoting its advanced services and increasing its client base in the Northern Europe region. Over the last few years, CAST PHARMA has positioned itself as an unique, advanced and highly professional company on the German pharmaceutical market. As result, this growing is a perfect fit for CAST PHARMA to expand its services and to position itself as the leading and the premier European 3D pharmaceutical and biomedical animation production company.

For further information, please visit:
http://www.cast-pharma.com

About CAST PHARMA
CAST PHARMA ia a premier European 3D pharmaceutical and biomedical animation production company. For more information, please visit www.cast-pharma.com.

Source: PharmaNews.eu

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...